Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

New score predicts complications after mild traumatic brain injury

3

Feb 2026

New score predicts complications after mild traumatic brain injury

A study led by researchers at the Institute for Research in Biomedicine of Lleida (IRBLleida), the University of Lleida (UdL), the Universitat Oberta de Catalunya (UOC) and Arnau de Vilanova University Hospital (HUAV) has developed and internally validated a clinical prediction model called the Goliat score, which can be used by emergency services to estimate the risk of acute complications in patients suffering from minor and moderate traumatic brain injuries (TBIs).

Poll: Many adults over 50 skip flu and COVID vaccines

3

Feb 2026

Poll: Many adults over 50 skip flu and COVID vaccines

This winter's brutal flu season isn't over, and COVID-19 cases have risen recently too. But a new poll taken in recent weeks shows that vaccination against both viruses lags among people 50 and over, and the national survey reveals key reasons why.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.